Papyrus Australia (ASX: PPY) has secured $175,000 through a share placement alongside convertible note conversions and related party loans, aiming to fund commercialisation and fulfil a key contract for biodegradable Collar Keeper® products.
- Placement of 17.5 million shares at $0.01 raising $175K
- Conversion of $263K in loans to secured convertible notes
- Related party loans of $150K to be converted pending shareholder approval
- Up to $536K additional secured convertible notes planned
- Funds targeted at commercialising biodegradable Collar Keeper® contract
Capital Raising to Support Commercialisation Push
Papyrus Australia has launched a multifaceted capital raising initiative designed to fuel its transition from development to commercial operations. The company will raise $175,000 via a placement of 17.5 million shares priced at $0.01 each, accompanied by 8.75 million unlisted options exercisable at $0.02 over two years. This price represents an 11% premium to the last traded price before a trading halt and aligns with the 15-day VWAP, signalling measured confidence in the company’s near-term prospects.
Alongside the placement, Papyrus is converting $263,846 of existing short-term loans from sophisticated investors into secured convertible notes, and seeking shareholder approval to convert $264,279 in related party loans into unsecured convertible notes. The company also plans to raise up to $536,154 more through additional secured convertible notes, pending shareholder consent. These convertible notes carry a 1% monthly interest rate and a maturity of two years, with conversion prices tied to share price thresholds and shareholder approval required for option grants on conversion.
Director Loans and Shareholder Approval on the Horizon
The EGM will also seek ratification of the prior issue of secured convertible notes and placement shares, a procedural but necessary step to maintain compliance and investor confidence. The company has agreed to broker fees of 6% for both the placement and convertible notes, reflecting standard market practice for raising capital in this manner.
Funding to Accelerate Collar Keeper® Production
Funds raised will underpin the commercialisation of Papyrus’s biodegradable Collar Keeper® products under contract with TBS Mining Solutions. This contract, announced late last year, marks a critical milestone in scaling production of environmentally friendly alternatives in the mining sector. The capital injection aims to ensure operational continuity and support the company’s ongoing scale-up activities, building on progress made with the Adelaide Rapid Prototyping & R&D Facility commissioned earlier this year.
This latest capital raising follows Papyrus’s recent efforts to strengthen its financial footing and commercial capabilities, including securing a $4.2 million supply contract and narrowing losses, as detailed in its earlier commercial scale-up with new R&D facility announcement. The company’s ability to convert loans into equity and options provides flexibility but also introduces dilution risks that shareholders will scrutinise closely.
Disclosure Breach and Compliance Measures
In a regulatory disclosure, Papyrus acknowledged a breach of ASX Listing Rule 3.1 for not announcing an extension of a $500,000 loan facility’s repayment date during ongoing negotiations. The ASX directed the company to disclose this, highlighting the importance of continuous disclosure in maintaining market integrity. Papyrus has committed to reviewing its disclosure policies and enhancing internal controls to prevent future lapses, aiming to rebuild trust with investors and regulators alike.
Bottom Line?
Papyrus’s capital raise and loan conversions provide essential funding for its commercial rollout but hinge on shareholder approval and disciplined execution amid regulatory scrutiny.
Questions in the middle?
- Will shareholder approval for loan conversions and unsecured notes materialise smoothly at the June EGM?
- How will the impending dilution from convertible notes and options impact share price momentum post-placement?
- Can Papyrus maintain compliance and investor confidence after its recent disclosure breach?